vs
monday.com Ltd.（MNDY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是monday.com Ltd.的1.1倍（$772.1M vs $704.0M），Revvity净利率更高（12.7% vs 1.3%，领先11.4%），monday.com Ltd.自由现金流更多（$224.6M vs $161.8M）
monday.com是总部位于以色列特拉维夫的云平台服务商，2014年正式推出核心产品，支持用户自定义搭建应用及项目管理工具。公司2019年完成1.5亿美元融资，估值达19亿美元，2021年6月正式公开上市。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MNDY vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$704.0M
净利率更高
RVTY
高出11.4%
1.3%
自由现金流更多
MNDY
多$62.8M
$161.8M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $704.0M | $772.1M |
| 净利润 | $9.4M | $98.4M |
| 毛利率 | 89.6% | — |
| 营业利润率 | -4.4% | 14.5% |
| 净利率 | 1.3% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MNDYRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $704.0M | $698.9M | ||
| Q2 25 | $453.0M | $720.3M | ||
| Q1 25 | $216.9M | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | $527.1M | $684.0M | ||
| Q2 24 | $337.9M | $691.7M | ||
| Q1 24 | $162.3M | $649.9M |
净利润MNDYRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $9.4M | $46.7M | ||
| Q2 25 | $21.4M | $53.9M | ||
| Q1 25 | $7.1M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $-14.2M | $94.4M | ||
| Q2 24 | $-21.7M | $55.4M | ||
| Q1 24 | $-14.7M | $26.0M |
毛利率MNDYRVTY
| Q4 25 | — | — | ||
| Q3 25 | 89.6% | 53.6% | ||
| Q2 25 | 89.6% | 54.5% | ||
| Q1 25 | 89.2% | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 89.0% | 56.3% | ||
| Q2 24 | 89.2% | 55.7% | ||
| Q1 24 | 89.5% | 54.6% |
营业利润率MNDYRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | -4.4% | 11.7% | ||
| Q2 25 | -0.7% | 12.6% | ||
| Q1 25 | -2.3% | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | -7.1% | 14.3% | ||
| Q2 24 | -10.3% | 12.4% | ||
| Q1 24 | -14.0% | 6.8% |
净利率MNDYRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 1.3% | 6.7% | ||
| Q2 25 | 4.7% | 7.5% | ||
| Q1 25 | 3.3% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | -2.7% | 13.8% | ||
| Q2 24 | -6.4% | 8.0% | ||
| Q1 24 | -9.0% | 4.0% |
每股收益（稀释后）MNDYRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.0B | $7.3B |
| 总资产 | $1.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MNDYRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $1.4B | $931.4M | ||
| Q2 25 | $1.7B | $991.8M | ||
| Q1 25 | $1.4B | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.3B | $2.0B | ||
| Q1 24 | $1.1B | $1.7B |
股东权益MNDYRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $1.0B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.0B | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | $813.5M | $7.9B | ||
| Q2 24 | $910.1M | $7.9B | ||
| Q1 24 | $813.5M | $7.8B |
总资产MNDYRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $1.7B | $12.1B | ||
| Q2 25 | $2.0B | $12.4B | ||
| Q1 25 | $1.7B | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | $1.3B | $12.8B | ||
| Q2 24 | $1.5B | $13.4B | ||
| Q1 24 | $1.3B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $234.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $224.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 31.9% | 21.0% |
| 资本支出强度资本支出/营收 | 1.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 25.02× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $608.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MNDYRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $234.4M | $138.5M | ||
| Q2 25 | $147.7M | $134.3M | ||
| Q1 25 | $92.0M | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | $156.9M | $147.9M | ||
| Q2 24 | $90.3M | $158.6M | ||
| Q1 24 | $42.7M | $147.6M |
自由现金流MNDYRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $224.6M | $120.0M | ||
| Q2 25 | $141.8M | $115.5M | ||
| Q1 25 | $90.5M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $151.4M | $125.6M | ||
| Q2 24 | $85.6M | $136.6M | ||
| Q1 24 | $39.2M | $129.7M |
自由现金流率MNDYRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 31.9% | 17.2% | ||
| Q2 25 | 31.3% | 16.0% | ||
| Q1 25 | 41.7% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | 28.7% | 18.4% | ||
| Q2 24 | 25.3% | 19.7% | ||
| Q1 24 | 24.1% | 20.0% |
资本支出强度MNDYRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 0.7% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 1.0% | 3.3% | ||
| Q2 24 | 1.4% | 3.2% | ||
| Q1 24 | 2.2% | 2.7% |
现金转化率MNDYRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 25.02× | 2.97× | ||
| Q2 25 | 6.91× | 2.49× | ||
| Q1 25 | 12.99× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MNDY
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
